LivaNova (LIVN) has drawn investor attention after recent share price moves, with the stock last closing at $78.74. That places the company’s market value near $4.34b in the medical technology space.

Recent trading has been choppy for LivaNova, with a 0.68% 1 day share price return and a 3.36% 7 day share price decline. However, the 29.85% year to date share price return and 39.73% 1 year total shareholder return point to momentum that has been building over a longer period.

If the medical technology story has your attention, this is a good moment to broaden your watchlist and check out 41 healthcare AI stocks

Bulls view LivaNova’s recent run and ongoing growth in revenue and net income as a sign the stock still has room, while bears point to past long term share price bumps. Which story fits the current valuation?

Most Popular Narrative: 7.1% Undervalued

Compared with LivaNova's last close at $78.74, the most widely followed narrative points to a fair value of $84.80, suggesting modest undervaluation based on its cash flow outlook and earnings potential.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Want to see what underpins that earnings story for LivaNova. The narrative hinges on steady top line expansion, broader margins, and a future profit multiple that assumes the market continues to rate its cash generation highly. Curious how those moving parts are combined into a single fair value number.

Result: Fair Value of $84.80 (UNDERVALUED)

However, LivaNova still faces pressure from healthcare cost controls and reimbursement scrutiny, along with competition that could affect procedure volumes, pricing power, and profitability.

Next Steps

Given the mix of optimism and concern around LivaNova, it makes sense to look at the full picture right now and decide where you stand. To weigh the balance of potential upsides and flagged issues in one place, review the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond LivaNova?

Do not stop with LivaNova. Use this moment of focus to widen your opportunity set with a few targeted stock ideas that match different priorities.

• Spot potential bargain opportunities before they are widely followed by checking the screener containing 18 high quality undiscovered gems.
• Prioritise stability and capital protection by reviewing companies in the 75 resilient stocks with low risk scores.
• Target balance sheet strength and business resilience by screening for companies in the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.